Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at...
March 09, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...
March 04, 2026 16:05 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals to Participate in Upcoming March Investor Events

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...
February 10, 2026 16:41 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General...
February 05, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Announces $100.0 Million Private Placement

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...
January 26, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals...
January 21, 2026 08:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for...
January 12, 2026 16:05 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice...
January 06, 2026 07:00 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for...
December 10, 2025 17:04 ET | Source: LB Pharmaceuticals Inc

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief...